Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 1:27 AM
Ignite Modification Date:
2025-12-25 @ 1:27 AM
NCT ID:
NCT02514694
Brief Summary:
LEO 32731 ("Study Drug") is an investigational drug which is being developed by LEO Pharma A/S ("the Sponsor") for treatment of psoriasis. The aim (s) of this Study are to determine:
* The safety and tolerability of the Study Drug and any side effects that might be associated with it
* The Study will also measure how much of the Study Drug that gets into the blood and how long time it takes for the body to remove it.
Study:
NCT02514694
Study Brief:
Protocol Section:
NCT02514694